Literature DB >> 12470609

The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils.

Mark C Lavigne1, Philip M Murphy, Thomas L Leto, Ji-Liang Gao.   

Abstract

N-Formylypeptides such as fMet-Leu-Phe (fMLF) potently induce superoxide production through NADPH oxidase activation. The receptors that mediate this response have not been defined. Here, we provide definitive proof using a mouse model that formyl peptide receptor (FPR) is a receptor, but not the only receptor, that mediates fMLF-induced oxidase activation. In wild-type (FPR(+/+)) mouse neutrophils, superoxide production is dependent on the concentration of fMLF with an EC(50) of approximately 5 microM and a peak at approximately 50 microM. In contrast, FPR-deficient (FPR(-/-)) mouse neutrophils produced markedly less superoxide with an EC(50) of approximately 50 microM and a peak at approximately 200 microM. Yet, FPR(+/+) and FPR(-/-) neutrophils showed similar oxidase activation kinetics and G(i) protein-dependent pharmacological sensitivities. These results suggested that a second receptor, likely FPR2, mediates superoxide production at high concentrations of fMLF. This less sensitive second pathway may permit continued oxidant generation in response to formyl peptides when FPR is desensitized in high concentrations of the chemotactic gradient.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470609     DOI: 10.1016/s0008-8749(02)00564-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Changes in activation states of murine polymorphonuclear leukocytes (PMN) during inflammation: a comparison of bone marrow and peritoneal exudate PMN.

Authors:  Takuya Itou; L Vincent Collins; Fredrik B Thorén; Claes Dahlgren; Anna Karlsson
Journal:  Clin Vaccine Immunol       Date:  2006-05

2.  Protective effects of n-6 fatty acids-enriched diet on intestinal ischaemia/reperfusion injury involve lipoxin A4 and its receptor.

Authors:  T Gobbetti; S Ducheix; P le Faouder; T Perez; F Riols; J Boue; J Bertrand-Michel; M Dubourdeau; H Guillou; M Perretti; N Vergnolle; N Cenac
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

3.  Leukocyte chemoattractant receptor FPR2 may accelerate atherogenesis.

Authors:  Wuzhou Wan; Ji-Liang Gao
Journal:  Med Hypotheses       Date:  2012-04-26       Impact factor: 1.538

Review 4.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

5.  ClC-3 and IClswell are required for normal neutrophil chemotaxis and shape change.

Authors:  A Paige Davis Volk; Christine K Heise; Jami L Hougen; Christopher M Artman; Kenneth A Volk; Deborah Wessels; David R Soll; William M Nauseef; Fred S Lamb; Jessica G Moreland
Journal:  J Biol Chem       Date:  2008-10-07       Impact factor: 5.157

6.  Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1.

Authors:  Fu-Chao Liu; Huang-Ping Yu; Yu-Ting Syu; Jia-You Fang; Chwan-Fwu Lin; Shih-Hsin Chang; Yen-Tung Lee; Tsong-Long Hwang
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

7.  Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells.

Authors:  Karsten Lücke; Isabell Yan; Sonja Krohn; Annika Volmari; Stefanie Klinge; Joanna Schmid; Valéa Schumacher; Oliver M Steinmetz; Stefan Rose-John; Hans-Willi Mittrücker
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

8.  Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling.

Authors:  Youwen Zhuang; Heng Liu; X Edward Zhou; Ravi Kumar Verma; Parker W de Waal; Wonjo Jang; Ting-Hai Xu; Lei Wang; Xing Meng; Gongpu Zhao; Yanyong Kang; Karsten Melcher; Hao Fan; Nevin A Lambert; H Eric Xu; Cheng Zhang
Journal:  Nat Commun       Date:  2020-02-14       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.